Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EGFR Gene Mutation Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

NCT06378658
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Esomeprazole, Food
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 22, 2026, 3:45 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819
View directory record Official record
Conditions
Advanced Solid Tumors, HER2 Mutation
Interventions
BAY2927088
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

NCT03846310
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions
Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 22, 2026, 3:45 PM EDT
Terminated Phase 1 Interventional

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
Interventions
BLU-701, osimertinib, carboplatin, pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 3:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Interventions
BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Gilbert, Arizona • Duarte, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

NCT01859026
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
MEK162, Erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 22, 2026, 3:45 PM EDT
Terminated Phase 1 Interventional

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT06685718
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
Interventions
BG-60366
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Recruiting Phase 2 Interventional

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689
View directory record Official record
Conditions
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions
TAS6417, CYP Cocktail, Transporter Cocktail
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients

NCT03236675
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Hollywood, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 22, 2026, 3:45 PM EDT
No Longer Available No phase listed Expanded access

AZD9291 US Expanded Access Program

NCT02451852
View directory record Official record
Conditions
EGFR T790M Mutation Positive NSCLC
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
Anaheim, California • Beverly Hills, California • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 22, 2026, 3:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

NCT02846792
View directory record Official record
Conditions
ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Nivolumab, Plinabulin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

NCT02926768
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
Interventions
CK-101
Drug
Lead sponsor
Checkpoint Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Sarasota, Florida • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT02947386
View directory record Official record
Conditions
EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab
Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 22, 2026, 3:45 PM EDT
Terminated Phase 1 Interventional

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

NCT03065387
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Everolimus, Neratinib, Palbociclib, Trametinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Duarte, California • Orange, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AZD9291 First Time In Patients Ascending Dose Study

NCT01802632
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced (Inoperable) Non Small Cell Lung Cancer
Interventions
AZD9291
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

NCT03744715
View directory record Official record
Conditions
NSCLC, Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Completed Phase 2 Interventional

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

NCT03732352
View directory record Official record
Conditions
EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 Wt Allele
Interventions
Fludeoxyglucose F-18, Osimertinib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 22, 2026, 3:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Active, not recruiting Phase 2 Interventional

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Osimertinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 3:45 PM EDT
Withdrawn No phase listed Observational

T790M Mutation Positive 2nd Line STandard of cAre Registry

NCT02368990
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Kentucky, Kentucky • Maryland City, Maryland • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 22, 2026, 3:45 PM EDT